Psychedelic Neuroscience
- 1st Edition, Volume 242 - November 26, 2018
- Editor: Tanya Calvey
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 8 1 4 2 5 5 - 4
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 1 4 2 5 6 - 1
We are in the midst of what is being called the ‘psychedelic renaissance’ with growing interest into how psychedelics alter consciousness, brain function and brain connectivity. Th… Read more
Purchase options
We are in the midst of what is being called the ‘psychedelic renaissance’ with growing interest into how psychedelics alter consciousness, brain function and brain connectivity. The acute, often profound, effects of the psychedelic experience can induce lasting improvements in mental health demonstrating that chemistry forms the basis of mystical experience, consciousness and mental wellbeing.
- This volume is a collection of chapters by world leaders in fields of neurobiology, neuropsychiatry, psychology, ethnography and pharmacology, addressing the neurobiological mechanisms of action of various classic and atypical psychedelics, their therapeutic potential as well as the possible risks associated with their use
Policy makers, mental health practitioners, neuroscience researchers, researchers from various fields of health science and the humanities, members of the public and psychonauts
1. An introduction to psychedelic neuroscience
Tanya Calvey and Fleur M. Howells
2. The renaissance in psychedelic research: What do preclinical models have to offer
Kevin S. Murnane
3. D-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders
Danilo De Gregorio, Justine P. Enns, Nicolas A. Nuñez, Luca Posa and Gabriella Gobbi
4. Common neural signatures of psychedelics: Frequency-specific energy changes and repertoire expansion revealed using connectome-harmonic decomposition
Selen Atasoy, Jakub Vohryzek, Gustavo Deco, Robin L. Carhart-Harris and Morten L. Kringelbach
5. A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder
Joseph Barsuglia, Martin Polanco, Robert Palmer, Benjamin Malcolm, Benjamin Kelmendi and Tanya Calvey
6. Advances and challenges in neuroimaging studies on the effects of serotonergic hallucinogens: Contributions of the resting brain
Felix Müller, Matthias E. Liechti, Undine E. Lang and Stefan Borgwardt
7. Neurocognitive effects of cannabis: Lessons learned from human experimental studies
Marco Colizzi and Sagnik Bhattacharyya
8. Ibogaine as a treatment for substance misuse: Potential benefits and practical dangers
John Martin Corkery
- Edition: 1
- Volume: 242
- Published: November 26, 2018
- Language: English
TC
Tanya Calvey
Dr. Tanya Calvey has a background in evolutionary neurobiology and lectures morphological anatomy in the Faculty of Health Sciences, University of the Witwatersrand. Tanya’s current research is on the neuropsychopharmacology of ibogaine and substance use disorders in humans and animals. Her research team is multidisciplinary and her research is funded by the South African Medical Research Council, the South African National Research Foundation and the International Society for Neurochemistry.
Tanya is also actively involved in developing neuroscience research in Africa. She is the Secretary of the Southern African Neuroscience Society and the co-founder of the Wits Cortex Club.
Affiliations and expertise
University of Witwatersrand, South AfricaRead Psychedelic Neuroscience on ScienceDirect